English ministers veto Alexion's ultra orphan Soliris
This article was originally published in Scrip
English health ministers have rejected orphan drugs advisor, AGNSS' recommendation endorsing Alexion's Soliris (eculizumab) for atypical hemolytic uremic syndrome (aHUS). The ministers want more advice on the drug's affordability and are sending it for review by NICE, despite concerns that the health technology appraisal institute's current methods are unsuitable for drugs for rare conditions.
You may also be interested in...
Orphan drugs "are falling through the cracks" of the UK’s market access process, Shire's country general manager tells the Pink Sheet and calls for urgent all-party remedial talks.
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.